Home > Insider Trading > Filing (0001735276-20-000008)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178670	Alnylam Pharmaceuticals Inc.	ALNY	Pharmaceutical Preparations (2834)	770602661

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1446125	Yvonne Greenstreet	675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-02-07	6,250	$42.22	12,458	No	4	M	Direct
Common Stock	Disposition	2020-02-07	6,250	$123.90	6,208	No	4	S	Direct
Common Stock	Acquisiton	2020-02-10	5,600	$42.22	11,808	No	4	M	Direct
Common Stock	Disposition	2020-02-10	9,892	$130.00	1,916	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Performance Stock Option 2016 (right to buy)	Disposition	2020-02-07	6,250	$0.00	6,250	$42.22
Common Stock	Performance Stock Option 2016 (right to buy)	Disposition	2020-02-10	5,600	$0.00	5,600	$42.22

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
12,500	2019-08-06	2026-12-20	No	4	M	Direct
6,900	2019-08-06	2026-12-20	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	407	Indirect	by Managed Account

Footnotes

All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 03, 2019.
Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.